cell therapy, immunology

Engineered natural killer cells track down cancer cells in the bone marrow.

An on-off enzyme switch controls metastasis in mice. 

Natural killer (NK) cells target infected and oncogenic cells, but are difficult to work with in vitro. Discover novel approaches to producing genetically modified NK cells for cell therapy. 

A cell’s metabolic program provides insight into its fitness and function.

An automated counterflow centrifugation–based technology outperforms manual peripheral blood mononuclear cell (PBMC) isolation.

Susan Thomas discusses how her team engineered a microfluidic device to screen for T cells with improved homing capability to tumor cells. 

Explore how to minimize error while dissociating cells and spheroids.

Discover how to monitor cell therapeutic potency during drug discovery and manufacturing.

A closed, automated system washes and concentrates cells destined for cell therapies and beyond.

Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells.

New technologies spur innovation in CAR T cell therapies.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

Scientists make hydrogel coats for individual cells that can be tailored to specific research questions.

Using patients’ own immune systems to fight cancer